MERCURE study: MEthotrexate in ReCurrent dVIN
The MERCURE study is investigating if a medication called methotrexate can prevent a skin condition known as dVIN from returning in women who have lichen sclerosus. dVIN is a vulvar skin condition that has recurred in these women. The study will carefully compare how often dVIN comes back when women are using methotrexate versus when they are not, using each patient as their own comparison to see if the medicine helps. Researchers will also track how long it takes for dVIN to return, observing any changes at regular intervals over 18 months. Additionally, the study will check for any side effects, how comfortable patients are, if their vulvar symptoms improve, and if they need to use fewer other skin treatments.
At a glance
What is this study about?
The MERCURE study is looking into a medicine called methotrexate for women who have a skin condition called dVIN that has come back multiple times. This dVIN condition is linked to another skin issue called lichen sclerosus, which affects the skin around the vagina. If you've been told you have dVIN that keeps returning, this study might be of interest.
The main aim of this study is to see if methotrexate can help stop dVIN from coming back. The researchers will be comparing how often dVIN returns when women are taking methotrexate versus when they are not. This is a special type of study where each patient acts as their own comparison, meaning the doctors will look at how your condition behaves both with and without the medicine over time. They will check on you regularly for about 18 months to see if the dVIN is stable (not getting worse) or progressing. This will help them understand if methotrexate is effective in preventing these recurring dVIN lesions.
Beyond simply tracking if dVIN comes back, the study will also pay close attention to other important things. They want to know if methotrexate causes any side effects and how well people tolerate the treatment. They'll also check if the medicine helps reduce any discomfort or itching you might be experiencing in your vulvar area, and if it means you can use fewer other skin creams or treatments. Your overall satisfaction with the treatment will also be an important part of the study. All of this information helps doctors understand the full picture of how methotrexate might help women with this condition.
Key takeaways
- This study explores a potential new treatment for recurrent dVIN linked to lichen sclerosus.
- It uses methotrexate to see if it reduces how often dVIN comes back.
- Participation involves taking methotrexate and having regular check-ups over 18 months.
- The study also monitors side effects, symptom relief, and patient satisfaction.
- This research helps understand if methotrexate can be a good option for dVIN.
- Each patient acts as their own comparison to show the medicine's effect.
Who may be eligible?
This study is specifically for women who are 18 years old or older. There is no upper age limit, meaning women of any adult age can potentially take part.
To be considered for this study, you must have been diagnosed with dVIN (differentiated Vulvar Intraepithelial Neoplasia) that has repeatedly come back, and this dVIN must be linked to lichen sclerosus. The researchers are looking for women who have experienced their dVIN recurring.
If you are a woman over 18, and have recurrent dVIN associated with lichen sclerosus, you might be eligible. The study ensures all participants fit these specific criteria to properly assess the effects of the treatment.
- Are you 18 years old or older?
- Are you a woman?
- Have you been diagnosed with dVIN around your vulva that keeps coming back?
- Is your dVIN linked to or caused by lichen sclerosus?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you take part in the MERCURE study, you will be given methotrexate tablets. The study is designed so that you will act as your own comparison – this means doctors will observe your dVIN both when you are using methotrexate and when you are not, to see if the medicine makes a difference.
You will have regular check-ups over an 18-month period. These visits will happen at 1, 3, 6, 9, 12, 15, and 18 months. During these visits, doctors will examine your dVIN to determine if it is stable or progressing. You will also be asked to fill out questionnaires about any side effects you experience, how your vulvar symptoms are, how much other treatments you are using, and your overall satisfaction with the treatment. The researchers may also look at previous or current skin samples (biopsies) you've had to learn more. The total duration of your active participation, including check-ups, will be 18 months.
Potential risks and benefits
Locations (1)
- —Netherlands
Common questions
What is dVIN?
dVIN stands for differentiated Vulvar Intraepithelial Neoplasia. It's a non-cancerous skin change that affects the skin around the vagina and can sometimes keep coming back.
What is lichen sclerosus?
Lichen sclerosus is a long-term skin condition that typically affects the skin around the vagina. It can cause thin, white patches of skin and can be itchy or uncomfortable.
What is methotrexate?
Methotrexate is a medicine that is used to treat a few different conditions, including some skin conditions and certain types of arthritis. In this study, doctors are investigating if it can help stop dVIN from returning.
How long will I be in the study?
If you join the study, you will be followed up for a total of 18 months, with regular visits and assessments.
Will I know if the medicine is working for me?
The study team will regularly assess your dVIN lesions during your visits and discuss any changes or improvements with you.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.